A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

NCT01323270 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

753

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Vaccine
rLP2086
Repevax
N Meningitidis Serogroup B
Meningitis

Interventions

BIOLOGICAL: rLP2086
BIOLOGICAL: Repevax
BIOLOGICAL: Saline
BIOLOGICAL: Repevax

Sponsor

Pfizer